Mini Curriculum Vitae

Guila DAYAN

PhotoDAYAN
Equipe : Dialogue cellules microenvironnement et réparation tissulaire
Courriel : guila.dayan@ibcp.fr
Téléphone : +33(0)4-37-65-29-27
Statut : Maître de conférences


2019
19.  Re-epithelialization of adult skin wounds: Cellular mechanisms and therapeutic strategies. 
Rousselle P, Braye F, Dayan G
(2019) Adv Drug Deliv Rev 146 :344-365  Icon PUBMED

2016
18.  Perlecan expression influences the keratin 15-positive cell population fate in the epidermis of aging skin. 
Dos Santos M, Michopoulou A, Andre-frei V, Boulesteix S, Guicher C, Dayan G, Whitelock J, Damour O, Rousselle P
(2016) Aging (albany Ny) 8 :751-68  Icon PUBMED

2014
17.  LKB1 when associated with methylatedER? is a marker of bad prognosis in breast cancer. 
Bouchekioua-bouzaghou K, Poulard C, Rambaud J, Lavergne E, Hussein N, Billaud M, Bachelot T, Chabaud S, Mader S, Dayan G, Treilleux I, Corbo L, Le Romancer M
(2014) Int J Cancer 135 :1307-18  Icon PUBMED

2013
16.  The syndecan binding sequence KKLRIKSKEK in laminin ?3 LG4 domain promotes epidermal repair. 
Rousselle P, Carulli S, Chajra H, Dayan G, Pin D, Herbage B
(2013) Eur J Dermatol  :  Icon PUBMED

2012
15.  Cell surface proteoglycans syndecan-1 and -4 bind overlapping but distinct sites in laminin ?3 LG45 protein domain. 
Carulli S, Beck K, Dayan G, Boulesteix S, Lortat-jacob H, Rousselle P
(2012) J Biol Chem 287 :12204-16  Icon PUBMED

2007
14.  Raloxifene and ICI182,780 increase estrogen receptor-alpha association with a nuclear compartment via overlapping sets of hydrophobic amino acids in activation function 2 helix 12 
Lupien M , Jeyakumar M , Hebert E , Hilmi K , Cotnoir-white D , Loch C , Auger A , Dayan G , Pinard Ga , Wurtz Jm , Moras D , Katzenellenbogen J , Mader S
(2007) Molecular Endocrinology 21 :797-816

2006
13.  Tamoxifen and raloxifene differ in their functional interactions with aspartate 351 of estrogen receptor alpha. 
Dayan G, Lupien M, Auger A, Anghel Si, Rocha W, Croisetiere S, Katzenellenbogen Ja, Mader S
(2006) Mol Pharmacol 70 :579-88  Icon PUBMED

2005
12.  Major cytogenetic aberrations and typical multidrug resistance phenotype of uveal melanoma: current views and new therapeutic prospects. 
Baggetto Lg, Gambrelle J, Dayan G, Labialle S, Barakat S, Michaud M, Grange Jd, Gayet L
(2005) Cancer Treat Rev 31 :361-79  Icon PUBMED

11.  Multidrug-resistant cancer cells contain two populations of P-glycoprotein with differently stimulated P-gp ATPase activities: evidence from atomic force microscopy and biochemical analysis. 
Barakat S, Gayet L, Dayan G, Labialle S, Lazar A, Oleinikov V, Coleman Aw, Baggetto Lg
(2005) Biochem J 388 :563-71  Icon PUBMED

10.  Uveal melanoma in an 18-year-old African black man. 
Gambrelle J, Dayan G, Baggetto Lg, Devouassoux-shisheboran M, Salle M, Labialle S, Gayet L, Barakat S, Kodjikian L, Grange Jd
(2005) Acta Ophthalmol Scand 83 :134-6  Icon PUBMED

9.  [Multidrug resistance in uveal melanoma]. 
Gambrelle J, Labialle S, Dayan G, Gayet L, Barakat S, Michaud M, Grange Jd, Baggetto Lg
(2005) J Fr Ophtalmol 28 :652-9  Icon PUBMED

8.  Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells. 
Gayet L, Dayan G, Barakat S, Labialle S, Michaud M, Cogne S, Mazane A, Coleman Aw, Rigal D, Baggetto Lg
(2005) Biochemistry 44 :4499-509  Icon PUBMED

7.  Characterization of the typical multidrug resistance profile in human uveal melanoma cell lines and in mouse liver metastasis derivatives. 
Labialle S, Dayan G, Gambrelle J, Gayet L, Barakat S, Devouassoux-shisheboran M, Bernaud J, Rigal D, Grange Jd, Baggetto Lg
(2005) Melanoma Res 15 :257-66  Icon PUBMED

6.  Gene therapy of the typical multidrug resistance phenotype of cancers: a new hope? 
Labialle S, Dayan G, Michaud M, Barakat S, Rigal D, Baggetto Lg
(2005) Semin Oncol 32 :583-90  Icon PUBMED

2004
5.  [Toward monosomy 3 as the main prognosis factor of uveal melanoma: current cytogenetic data]. 
Gambrelle J, Labialle S, Dayan G, Gayet L, Barakat S, Grange Jd, Baggetto Lg
(2004) J Fr Ophtalmol 27 :1061-7  Icon PUBMED

4.  New invMED1 element cis-activates human multidrug-related MDR1 and MVP genes, involving the LRP130 protein. 
Labialle S, Dayan G, Gayet L, Rigal D, Gambrelle J, Baggetto Lg
(2004) Nucleic Acids Res 32 :3864-76  Icon PUBMED

2003
3.  RU49953: a non-hormonal steroid derivative that potently inhibits P-glycoprotein and reverts cellular multidrug resistance. 
Perez-victorias Fj, Conseil G, Munoz-martinez F, Perez-victoria Jm, Dayan G, Marsaud V, Castanys S, Gamarro F, Renoir Jm, Di Pietro A
(2003) Cell Mol Life Sci 60 :526-35  Icon PUBMED

1999
2.  Correlation between the affinity of flavonoids binding to the cytosolic site of Leishmania tropica multidrug transporter and their efficiency to revert parasite resistance to daunomycin. 
Perez-victoria Jm, Chiquero Mj, Conseil G, Dayan G, Di Pietro A, Barron D, Castanys S, Gamarro F
(1999) Biochemistry 38 :1736-43  Icon PUBMED

1996
1.  Recombinant N-terminal nucleotide-binding domain from mouse P-glycoprotein. Overexpression, purification, and role of cysteine 430. 
Dayan G, Baubichon-cortay H, Jault Jm, Cortay Jc, Deleage G, Di Pietro A
(1996) J Biol Chem 271 :11652-8  Icon PUBMED